Considerations For Patients Receiving Long-Acting Injectable Antipsychotics During COVID-19
In this presentation, René Kahn, MD, PhD, PsychU Schizophrenia Section Advisor, discusses the impact of COVID-19 on long-acting injectable (LAI) antipsychotic administration, including safety and clinical considerations. Dr. Kahn will also discuss the personal protective equipment (PPE) recommendations from the Substance Abuse and Mental Health Services Administration (SAMHSA).
Download Resource
René Kahn, MD, PhD, is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.Jehan Marino, PharmD, BCPP, is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
![](https://psychu.org/wp-content/uploads/2021/01/PsychU_watch-1024x576-1.jpg)